Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • The average cost in 2004 per age-related macular degeneration (AMD) patient age 40 to 64 using outpatient services was $305. The average cost per patient 65 years and older was…  
  • Individuals with early-stage age-related macular degeneration (AMD) are almost 2 times more likely to have a stroke than those who do not have the eye disease.  
  • The annual cost of adult vision problems in the U.S. is around $51.4 billion.  
  • From 2005 – 2008, around 4.2 million diabetics age 40 and older had diabetic retinopathy.  Of these, 655,000 had advanced diabetic retinopathy that could lead to severe vision loss.  
  • Future Impact of DR
    The rise of DR will disproportionately impacting the poorest populations, since 80% of people with diabetes live in low-middle income countries.